Revival of old antibiotics: Structuring the re-development process to optimize usage

Clinical Microbiology and Infection

Volumn 21, Issue 10, 2015, Pages 878-880

  Theuretzbacher, U ^a   Paul, M ^b  

^a Centre for Anti Infective Agents   (Austria)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Carbapenem resistance; Drug redevelopment; Multidrug resistant bacteria; Pharmacokinetics pharmacodynamics; Regulatory drug approval

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; DRUG APPROVAL; DRUG INDICATION; EDITORIAL; PHARMACODYNAMICS; PRIORITY JOURNAL; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMAN; MULTIDRUG RESISTANCE; STAPHYLOCOCCAL INFECTIONS;

ANTI-BACTERIAL AGENTS; DRUG APPROVAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; STAPHYLOCOCCAL INFECTIONS;

EID: 84942192351     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1016/j.cmi.2015.06.019     Document Type: Editorial

References (17)

1. Theuretzbacher U., Van Bambeke F., Cantón R., Giske C.G., Mouton J.W., Nation R.L., et al. Reviving old antibiotics. J Antimicrob Chemother 2015 Jun 10, pii: dkv157 [Epub ahead of print].
2. Couet W., Gregoire N., Marchand S., Mimoz O. Colistin pharmacokinetics: the fog is lifting. Clin Microbiol Infect 2012, 18:30-39.
3. Sime F.B., Roberts M.S., Roberts J.A. Optimisation of dosing regimens and dosing in special populations. Clin Microbiol Infect 2015, 21:886-893.
4. Muller A.E., Theuretzbacher U., Mouton J.W. Usage of old antibiotics now and in the future from a PK/PD perspective. Clin Microbiol Infect 2015, 21:881-885.
5. Huttner A., Verhaegh E., Harbarth S., Muller A.E., Theuretzbacher U., Mouton J.W. Nitrofurantoin revisited: a systematic review and meta-analysis of randomised controlled trials. J Antimicrob Chemother 2015 Jun 11, pii: dkv147 [Epub ahead of print].
6. Falagas M.E., Vouloumanou E.K., Togias A.G., Karadima M., Kapaskelis A.M., Rafailidis P.I., et al. Fosfomycin versus other antibiotics for the treatment of cystitis: a meta-analysis of randomized controlled trials. J Antimicrob Chemother 2010, 65:1862-1877.
7. Eliakim-Raz N., Lador A., Leibovici-Weissman Y., Elbaz M., Paul M., Leibovici L. Efficacy and safety of chloramphenicol: joining the revival of old antibiotics? Systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother 2015, 70:979-996.
8. Yahav D., Farbman L., Leibovici L., Paul M. Colistin: new lessons on an old antibiotic. Clin Microbiol Infect 2012, 18:18-29.
9. Paul M., Bishara J., Yahav D., Goldberg E., Neuberger A., Ghanem-Zoubi N., et al. Trimethoprim-sulfamethoxazole versus vancomycin for severe infections caused by methicillin resistant Staphylococcus aureus: randomised controlled trial. BMJ 2015, 350:h2219.
10. Pontikis K., Karaiskos I., Bastani S., Dimopoulos G., Kalogirou M., Katsiari M., et al. Outcomes of critically ill intensive care unit patients treated with fosfomycin for infections due to pandrug-resistant and extensively drug-resistant carbapenemase-producing gram-negative bacteria. Int J Antimicrob Agents 2014, 43:52-59.
11. Laterre P.F., François B. Strengths and limitations of industry vs. academic randomised controlled trials. Clin Microbiol Infect 2015, 21:906-909.
12. Pulcini C., Bush K., Craig W.A., Frimodt-Møller N., Grayson M.L., Mouton J.W., et al. Forgotten antibiotics: an inventory in Europe, the United States, Canada, and Australia. Clin Infect Dis 2012, 54:268-274.
13. Nation R.L., Li J., Cars O., Dudley M.N., Kaye K.S., Mouton J.W., et al. Framework for optimisation of the clinical use of colistin and polymyxin B: the Prato polymyxin consensus. Lancet Infect Dis 2015, 15:225-234.
14. Capone A., Giannella M., Fortini D., Giordano A., Meledandri M., Ballardini M., et al. High rate of colistin resistance among patients with carbapenem-resistant Klebsiella pneumoniae infection accounts for an excess of mortality. Clin Microbiol Infect 2013, 19:E23-E30.
15. Giske C.G. Contemporary resistance trends and mechanisms for colistin, temocillin, fosfomycin, mecillinam and nitrofurantoin. Clin Microbiol Infect 2015, 21:899-905.
16. Andersson D.I. Improving predictions of the risk of resistance development against new and old antibiotics. Clin Microbiol Infect 2015, 21:894-898.
17. Theuretzbacher U. Product information for parenteral colistin varies substantially across Europe. J Antimicrob Chemother 2014, 69:1987-1992.